{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-040447","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-06-03T20:43:17+00:00","discovered_at":"2026-06-03T20:44:00.483428+00:00","generated_at":"2026-06-03T21:04:51.051853+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Acumen stockholders elect three Class II directors, approve equity plan","bullets":["Elected Golumbeski (37.3M for), Porter (30.9M for), Stoppel (30.8M for) as Class II directors.","Ratified Ernst & Young as auditor for FY 2026: 56.9M for, 113k against.","Approved Amended and Restated 2021 Equity Incentive Plan: 30.7M for, 6.6M against, 19.7M broker non-votes.","Turnout: 57.1M of 72.2M shares (78.99%) present or represented at annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-040447","json":"https://secwatch.observer/filing/0001628280-26-040447.json","markdown":"https://secwatch.observer/filing/0001628280-26-040447.md","text":"https://secwatch.observer/filing/0001628280-26-040447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/abos-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:04:51.051853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"221eb63e1208241e5531040a131b70eaf5dd4763","claim":"Acumen Pharmaceuticals, Inc. shareholders approved Election of three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-03 meeting.","evidence_excerpt":"Proposal No. 1: The stockholders elected three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes George Golumbeski, Ph.D. 37,305,711 68,820 19,676,925","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"b8e596e10ddf5ec2226716da8db55815c564c21f","claim":"Acumen Pharmaceuticals, Inc. shareholders approved Approval of the Company's Amended and Restated 2021 Equity Incentive Plan. at the 2026-06-03 meeting.","evidence_excerpt":"Proposal No. 3 : The stockholders approved the Company’s Amended and Restated 2021 Equity Incentive Plan. The votes were cast as follows: Votes For Votes Against Abstained Broker Non-Votes Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan 30,731,776 6,618,621 24,134 19,676,925","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"},{"claim_id":"f9ab2c02b7b381fd670fd092943d12d8145a4dd4","claim":"Acumen Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.","evidence_excerpt":"Proposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 56,934,900 113,074 3,482","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026040447/0001628280-26-040447-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}